AU2011336360A1 - Compositions and methods for treating amyloid plaque associated symptoms - Google Patents

Compositions and methods for treating amyloid plaque associated symptoms Download PDF

Info

Publication number
AU2011336360A1
AU2011336360A1 AU2011336360A AU2011336360A AU2011336360A1 AU 2011336360 A1 AU2011336360 A1 AU 2011336360A1 AU 2011336360 A AU2011336360 A AU 2011336360A AU 2011336360 A AU2011336360 A AU 2011336360A AU 2011336360 A1 AU2011336360 A1 AU 2011336360A1
Authority
AU
Australia
Prior art keywords
seq
antibody
amino acid
apoe
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011336360A
Other languages
English (en)
Inventor
Adam Eltorai
David Holtzman
Hong Jiang
Jungsu Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Washington University in St Louis WUSTL
Original Assignee
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Washington University in St Louis WUSTL filed Critical Washington University in St Louis WUSTL
Publication of AU2011336360A1 publication Critical patent/AU2011336360A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2011336360A 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms Abandoned AU2011336360A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41906010P 2010-12-02 2010-12-02
US61/419,060 2010-12-02
US201161548542P 2011-10-18 2011-10-18
US61/548,542 2011-10-18
PCT/US2011/063121 WO2012075422A2 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Publications (1)

Publication Number Publication Date
AU2011336360A1 true AU2011336360A1 (en) 2013-07-04

Family

ID=46172597

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011336360A Abandoned AU2011336360A1 (en) 2010-12-02 2011-12-02 Compositions and methods for treating amyloid plaque associated symptoms

Country Status (14)

Country Link
US (2) US20140037638A1 (https=)
EP (1) EP2646053A4 (https=)
JP (1) JP2014502276A (https=)
KR (1) KR20140017513A (https=)
CN (1) CN103338786A (https=)
AU (1) AU2011336360A1 (https=)
BR (1) BR112013013723A2 (https=)
CA (1) CA2819679A1 (https=)
MX (1) MX2013006116A (https=)
NZ (1) NZ611614A (https=)
RU (1) RU2013130002A (https=)
SG (1) SG190952A1 (https=)
WO (1) WO2012075422A2 (https=)
ZA (1) ZA201303996B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2847218A4 (en) * 2012-05-08 2015-12-30 Univ Ramot APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES
WO2016054247A1 (en) 2014-09-30 2016-04-07 Washington University Tau kinetic measurements
EP3452074A4 (en) * 2016-05-03 2019-12-11 University of South Florida COMPOSITIONS AND METHOD FOR MODULATING THE ABETA PROTEIN
CA3042236A1 (en) 2016-10-28 2018-05-03 Washington University Anti-apoe antibodies
EP3655026A4 (en) 2017-07-17 2021-07-28 Janssen Biotech, Inc. ANTIGBINDING REGIONS AGAINST FIBRONECTIN TYPE III DOMAINS AND METHOD OF USING THEREOF
AU2020282792B2 (en) * 2019-05-28 2025-12-04 Banner Health ApoE antibodies, fusion proteins and uses thereof
US20240400659A1 (en) * 2021-10-19 2024-12-05 Bioatla, Inc. Conditionally active proteins for neurodegenerative diseases
JP2025540077A (ja) * 2022-11-30 2025-12-11 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ ナチュラルキラー細胞エンゲージャー
WO2026019667A1 (en) * 2024-07-17 2026-01-22 Jn Biosciences Llc Trispecific antibodies for activation of immune cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3265577B2 (ja) * 1992-10-13 2002-03-11 デューク・ユニバーシティ アポリポ蛋白ｅの４型イソ型の測定法
RU2006122946A (ru) * 2003-11-28 2008-01-10 Астразенека Аб (Se) Антитела
EP1736162A1 (en) * 2004-03-30 2006-12-27 Renomedix Institute Inc. Remedy for prion disease and method of producing the same
US20070248599A1 (en) * 2006-02-21 2007-10-25 Jordan Tang Treatment of alzheimer's disease with inhibitors of apoe binding to apoe receptor
CA2672581A1 (en) * 2006-12-14 2008-06-19 Forerunner Pharma Research Co., Ltd. Anti-claudin 3 monoclonal antibody and treatment and diagnosis of cancer using the same
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
EP2542581A4 (en) * 2010-03-01 2014-01-22 David Gladstone Inst APOLIPOPROTEIN-SPECIFIC ANTIBODY AND METHOD OF USE THEREOF

Also Published As

Publication number Publication date
WO2012075422A3 (en) 2012-10-04
MX2013006116A (es) 2013-10-17
NZ611614A (en) 2015-07-31
EP2646053A2 (en) 2013-10-09
ZA201303996B (en) 2015-10-28
US20140037638A1 (en) 2014-02-06
KR20140017513A (ko) 2014-02-11
CA2819679A1 (en) 2012-06-07
WO2012075422A2 (en) 2012-06-07
JP2014502276A (ja) 2014-01-30
BR112013013723A2 (pt) 2019-09-24
EP2646053A4 (en) 2014-05-28
US20160355581A1 (en) 2016-12-08
RU2013130002A (ru) 2015-01-10
CN103338786A (zh) 2013-10-02
SG190952A1 (en) 2013-07-31

Similar Documents

Publication Publication Date Title
US20160355581A1 (en) Compositions and methods for treating amyloid plaque associated symptoms
AU2006319358B2 (en) Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
TWI705975B (zh) 抗－N3pGlu類澱粉β肽抗體及其用途
US20230416393A1 (en) Cd6 antibody for treatment of t-cell mediated diseases or disorders
CN1426423B (zh) 螯合淀粉样蛋白β肽的人源化抗体
JP6955721B2 (ja) ＲＧＭａ結合タンパク質及びその使用
US8741298B2 (en) APOE immunotherapy
US7122374B1 (en) Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
CN112166121B (zh) 神经生长因子的单克隆抗体及其编码基因和应用
US20100322932A1 (en) Methods for amyloid removal using anti-amyloid antibodies
JP2010159284A (ja) 抗アミロイド抗体を用いるアミロイドの除去方法
CA3077304C (en) Anti-pacap antibody
US20140127225A1 (en) Compositions and methods for treating diseases of protein aggregation involving ic3b deposition
CN115175932B (zh) 用于治疗阿尔茨海默病的中和抗β淀粉样蛋白抗体
AU2023200728A1 (en) Prevention or treatment method for peripheral neuropathy or pain accompanying disease in which peripheral neuropathy or astrocyte disorder is recognized
JP2852705B2 (ja) 自己免疫疾患の治療
JP2024506409A (ja) 抗体
WO2025119350A1 (zh) 靶向Tau的特异性结合蛋白及其应用
US20230090965A1 (en) Prophylactic or therapeutic agent for dementia
AU2012201856A1 (en) Anti-Abeta globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
HK40005250A (en) Compositions and methods for treating spinal muscular atrophy
MX2008007149A (en) Therapeutic vaccine

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted